BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
read more...
Dec 04, 2024
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
read more...
Dec 02, 2024
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
read more...
Nov 27, 2024
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
read more...
Nov 26, 2024
BeiGene to Present at Upcoming Investor Conferences
read more...
Nov 19, 2024
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
read more...
Nov 14, 2024
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
read more...
Nov 12, 2024
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
read more...
Nov 06, 2024
BeiGene to Present at the Jefferies London Healthcare Conference
read more...
Nov 05, 2024
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
read more...
Oct 28, 2024
BeiGene Mourns Death of Beloved Board Member Donald Glazer
read more...
Oct 23, 2024
BeiGene Named Manufacturer of the Year by the National Association of Specialty Pharmacy (NASP)
read more...
Oct 21, 2024
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
read more...
Oct 16, 2024
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
read more...
Oct 04, 2024
BeiGene Announces Availability of TEVIMBRA® in U.S.
read more...
Sep 26, 2024
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
read more...
Sep 26, 2024
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
read more...
Sep 17, 2024
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
read more...
